HISOAR(SZ:002099)2022-12-06 01:31Group 1: Company Overview - The company has undergone restructuring and is now a dual-driven listed company in pharmaceuticals and dyes, with both sectors contributing similarly to revenue, although dyes have a larger profit share [3] - The dye project with a capacity of 30,000 tons has received environmental approval and construction is underway [3] - The company aims for both organic growth and external mergers and acquisitions to achieve rapid growth [3] Group 2: Investment Strategy - Recent external investments have been small and non-controlling, focusing on internal management and resource integration post-restructuring [3] - The company invested in Rixing Biotechnology, a major producer of anthraquinone intermediates, aligning with its industry background [3] - The company is cautious about external investments, seeking to leverage professional institutions for suitable targets and considering integration into the listed company structure only after thorough evaluation [4] Group 3: Market Position and Pricing - The company produces active dyes, distinguishing itself from competitors who only handle specific segments, and holds significant pricing power in the market [4] - It is the largest global producer of the active dye KN-R, which is expected to maintain stable pricing in the short term [4]